...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Alcohol >Oral delivery of ivermectin using a fast dissolving oral film: Implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder
【24h】

Oral delivery of ivermectin using a fast dissolving oral film: Implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder

机译：使用快速溶解的口腔膜口服依维菌素的口服给药：重新应用依维菌素作为药物治疗酒精使用障碍的意义

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Individuals suffering from an alcohol-use disorder (AUD) constitute a major health concern. Preclinical studies in our laboratory show that acute and chronic intraperitoneal (i.p.) administration of ivermectin (IVM) reduces alcohol intake and preference in mice. To enable clinical investigation to use IVM for the treatment of an AUD, development of an oral formulation that can be used in animals as well as longterm preclinical toxicology studies are required. The present work explores the use of a promising alternative dosage form of IVM, fast-dissolving oral films (Cure Pharmaceutical (R)), to test the efficacy and safety of oral IVM in conjunction with alcohol exposure. We tested the effect of IVM (0.21 mg) using a fast-dissolving oral film delivery method on reducing 10% v/v alcohol (10E) intake in female C57BL/6 mice using a 24-h access two-bottle choice paradigm for 6 weeks (5 days per week). Differences in ethanol intake, preference for ethanol, water intake, fluid intake, food intake, changes in mouse and organ weights, as well as histological changes to kidney, liver, and brain were analyzed. The IVM group drank significantly less ethanol over the 30-day period compared to the placebo (blank strip) and the no-treatment groups. Organ weights did not differ between the groups. Histological evaluation showed no differences in the brain and kidney between groups. In the liver, there was a slight increase in the incidence of microvesicular fatty and degenerative changes of the animals receiving the thin strips. No overt hepatocellular necrosis or perivascular inflammation was noted. Overall, these data support the use of this novel method of oral drug delivery for longer-term studies and should facilitate FDA required preclinical testing that is necessary to repurpose IVM for treatment of an AUD. (C) 2015 Elsevier Inc. All rights reserved.
机译：患有酒精使用障碍（AUD）的个人构成了主要的健康问题。我们实验室的临床前研究表明，伊维菌素（IVM）的急性和慢性腹膜内（i.p.）给药可降低小鼠的酒精摄入和偏好。为了使临床研究能够将IVM用于治疗AUD，需要开发可用于动物的口服制剂以及长期的临床前毒理学研究。本工作探索了有前途的IVM替代剂型，速溶口腔膜（Cure Pharmaceutical（R））的使用，以测试口服IVM与酒精接触的功效和安全性。我们使用24小时进入两瓶选择范式对6种雌性C57BL / 6小鼠使用快速溶解的口腔膜递送方法测试了IVM（0.21 mg）对减少10％v / v酒精（10E）摄入的影响周（每周5天）。分析了乙醇摄入量，乙醇偏好，水摄入量，液体摄入量，食物摄入量，小鼠和器官重量的变化以及肾脏，肝脏和大脑的组织学变化的差异。与安慰剂组（空白）和未治疗组相比，IVM组在30天的时间内所喝的乙醇明显减少。两组之间的器官重量没有差异。组织学评估显示两组之间的脑和肾没有差异。在肝脏中，接受细条的动物的微泡脂肪和变性变化的发生率略有增加。没有发现明显的肝细胞坏死或血管周围炎症。总体而言，这些数据支持使用这种新颖的口服药物递送方法进行长期研究，并应促进FDA要求的临床前测试，这对于将IVM重新用于治疗AUD是必需的。 （C）2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号